This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

REMARKS

Claims 40-68 are active in this application. The claims in this application are drawn to non-elected Group I in the parent application U.S. serial no. 09/636,060. Support for these claims is found in Claims 1-4, 28 and 34 (Group I) and the specification on pages 17, 18, 19 and 26. No new matter is added.

For reference, the sequences of the N-acetylglucosamine-1-phosphotransferase described in the specification and provided in the Sequence Listing are summarized in the Table below:

SEQ ID NO	ТҮРЕ	Source	Description
1	Amino acid	Human	α subunit
2	Amino acid	Human	$oldsymbol{eta}$ subunit
3	Amino acid	Human	γ subunit
4	Nucleic acid	Human	α/β cDNA
	•		(nt 165-2948-α subunit
			nt 2949 3932 β subunit)
5	Nucleic acid	Human	γ subunit cDNA
			(nt 96-941)
8	Amino acid	Mouse	$oldsymbol{eta}$ subunit
9	Amino acid	Mouse	γ subunit
10	Nucleic acid	Mouse	· γ subunit
15 .	Amino acid	Mouse	α subunit
16	Nucleic acid	Mouse	α/β cDNA
11	Amino acid	Rat	lpha eta eta
12	Nucleic acid	Rat	α/β cDNA
13	Amino acid	Drosophila	α/β
17	Nucleic acid	Drosophila	α/β cDNA

The paper copy of the Sequence Listing in this application is identical to the computer readable Sequence Listing filed in parent application U.S. serial no. 09/636,060, which was filed October 10, 2000. In accordance with 37 CFR § 1.821 (e), please use the last-filed computer readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary

change in application number and filing date for the instant application. A paper copy of the Sequence Listing is attached.

The specification has been amended to include the deposit information for the hybridoma cell lines, which is supported by the confirmation of deposit obtained from the American Type Tissue Collection in Manassas, Virginia filed in the parent application.

An action on the merits and allowance of the claims is solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER AND NEUSTADT, P.C.

Richard L. Chinn, Ph.D. Registration No. 34,305 Attorney of Record

Daniel J. Pereira, Ph.D. Registration No. 45,518

22850

Tel.: (703) 413-3000 Fax: (703) 413-2220